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Abstract
Background: For shared decision making doctors need to communicate the effectiveness of
therapies such that patients can understand it and discriminate between small and large effects.
Previous research indicates that patients have difficulties in understanding risk measures. This study
aimed to test the hypothesis that lay people may be able to discriminate between therapies when
their effectiveness is expressed in terms of postponement of an adverse disease event.
Methods:  In 2004 a random sample of 1,367 non-institutionalized Danes aged 40+ was
interviewed in person. The participants were asked for demographic information and asked to
consider a hypothetical preventive drug treatment. The respondents were randomized to the
magnitude of treatment effectiveness (heart attack postponement of 1 month, 6 months, 12
months, 2 years, 4 years and 8 years) and subsequently asked whether they would take such a
therapy. They were also asked whether they had hypercholesterolemia or had experienced a heart
attack.
Results:  In total 58% of the respondents consented to the hypothetical treatment. The
proportions accepting treatment were 39%, 52%, 56%, 64%, 67% and 73% when postponement was
1 month, 6 months, 12 months, 2 years, 4 years and 8 years respectively. Participants who thought
that the effectiveness information was difficult to understand, were less likely to consent to therapy
(p = 0.004).
Conclusion: Lay people can discriminate between levels of treatment effectiveness when they are
presented in terms of postponement of an adverse event. The results indicate that such
postponement is a comprehensible measure of effectiveness.
Background
Prevention and treatment of chronic disease processes
such as atherosclerosis, diabetes and osteoporosis repre-
sent an important challenge for health care systems in
most countries. Preventive interventions, however, often
need to be long lasting or even life long in order to realize
their full potential [1]. There is evidence that many
patients discontinue therapy because they are not con-
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vinced about their need for treatment, consider the effi-
cacy to be poor or experience adverse events [2]. Also,
patients with dyslipidaemia are more likely to discontinue
medication in primary than in secondary prevention [3].
This pattern of discontinuation may partly reflect lack of
ability to judge the effectiveness amongst patients. It is
therefore important to develop quantitative measures for
risk reduction such that clinicians as well as lay people
understand them.
There is evidence that involvement of the patient in deci-
sions about therapy increases adherence to therapies for
chronic diseases [4,5]. Shared decision making, however,
requires that patients are able to understand and respond
to the information provided by the doctor. This is not an
easy task in the context of chronic disease processes
because patients cannot judge the effectiveness from their
own experiences. Traditionally, effectiveness has been
expressed in risk terms such as absolute risk reduction
(ARR), its reciprocal the number needed to treat (NNT) or
relative risk reduction (RRR). There is an increasing body
of evidence to suggest that preferences for or opinions
about a therapy depends on the way it is presented. A ther-
apy may be judged as more favorable when it is presented
in terms of RRR than ARR or NNT even when the underly-
ing effectiveness is the same [6-8]. This could indicate that
these risk measures are difficult to comprehend. Indeed,
there is evidence that lay people and professionals may
have difficulties understanding risk measures [9-12].
More recently, natural frequencies and pictorial represen-
tation have shown promising results in terms of compre-
hensibility [9].
When an intervention (e.g. life style change or pharma-
ceutical) reduces the risk of adverse outcomes, it implies
that these adverse outcomes are postponed or even
avoided. While fatal outcomes cannot be avoided in the
long run, outcomes such as myocardial infarction may be
postponed to the extent that the patient dies from another
cause before he/she experiences them. Postponements of
adverse outcomes (death, heart attack, hip fracture, etc.)
are therefore an alternative way of expressing the effective-
ness of interventions for chronic disease processes. Such
postponements can be estimated on the basis of clinical
trials where the area between the (event free) survival
curves represents the mean postponement. It is conceiva-
ble that people understand postponement of adverse out-
comes better than risk reductions because we are used to
judging time and can easily distinguish for example one
week from one month or one year. The benefit in terms of
average postponement of hip fractures from osteoporosis
intervention was estimated at 12 days when an interven-
tion that reduces the risk of hip fracture by 50%, was ini-
tiated at the age of 50 and continued for one year [13]. If
treatment was initiated at ages 60, 70, 80 or 90 years aver-
age postponement of hip fracture would be 23, 55, 90,
and 74 days respectively. If treatment lasted for 10 years
the average postponement was estimated at 146, 260,
369, 373, and 167 days respectively [13]. In a later study
the findings suggested that laypersons were able to dis-
criminate between levels of osteoporosis intervention
effectiveness when it was presented in terms of hip frac-
ture postponement rather than NNT [14].
In the Scandinavian Simvastatin Survival Study [15] NNT
to avoid one case of myocardial infarction or heart attack
was nine over the 5.4 years median follow-up period. This
may be translated into an average postponement of myo-
cardial infarction of 3 months [16].
The aim of the present study was to explore whether lay
people are able to understand information on interven-
tion effectiveness in the sense that they are able to discrim-
inate between different magnitudes of postponement. The
hypothesis was that lay people's preferences for a preven-
tive therapy against heart attack were influenced by the
magnitude of its effect when they are expressed in terms of
postponement of disease.
Methods
A random sample of non-institutionalised individuals
aged 40 or more was invited to an in-person interview in
the spring of 2004. The sample was drawn from Statistics
Denmark's list of inhabitants. The population was divided
in 42 geographic strata, and respondents were drawn from
each stratum to ensure geographic representativity. The
interviews were performed by Gallup TNS as part of its
interview business, and no specific ethical approval was
required. Interviews were undertaken in the respondents'
homes, and up to three calls were made to obtain an inter-
view. The total sample was 3,111 persons. Of these indi-
viduals 54 (2%) were not fluent in Danish, 136 (4%) were
ill, demented or had hearing impairment and 178 (6%)
had addresses that were non-inhabited, non-existing or
used for industrial purposes. Of the remaining 2,743 indi-
viduals, 591 (22%) could not be contacted and 785
(28%) refused to participate. In total 1,367 of 2,743
(50%) subjects were interviewed in their homes.
The respondents were asked for sociodemographic back-
ground variables such as gender, age, education and
household income. In addition they were asked whether
they had experienced a heart attack or were diagnosed
with hypercholesterolemia. Eventually the interviewer
presented one of the two following statements orally and
written on a card:
A (the extended version): "Imagine that your physician
tells you that you have a somewhat increased cholesterol
level, and that on average 50% of all patients with a simi-BMC Medical Informatics and Decision Making 2007, 7:8 http://www.biomedcentral.com/1472-6947/7/8
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lar cholesterol level will suffer a heart attack during their
lifespan. You can not predict which patient will suffer a
heart attack. Heart attack is rarely seen in patients less than
50 years old and the majority of patients are more than 70
years old.
The physician presents you with a medication which
should be taken once a day. The medication has only few
and harmless side effects. If you take the treatment, you
will need to visit your doctor once a year. The medication
will cost you DKK 500 (€1.00≈7, 54 DKK) per year.
The medication postpones a heart attack by approxi-
mately (for example) 1 month, if you continue the treat-
ment for the rest of your life.
Would you choose to accept such treatment?"
Or
B (the limited version): "Imagine that your physician
tells you that you have a somewhat increased cholesterol
level and an increased risk of suffering a heart attack. The
physician presents you with a medication which should
be taken once a day. The medication has only few and
harmless side effects. If you take the treatment, you will
need to visit your doctor once a year. The medication will
cost you DKK 500 per year.
The medication postpones a heart attack by approxi-
mately (for example) 1 month if you continue the treat-
ment for the rest of your life.
Would you choose to accept such treatment?"
The respondents could answer "yes", "no" or "not certain/
do not know".
The respondents were randomly assigned to postpone-
ment of either 1 month, 6 months, 12 months, 2 years, 4
years or 8 years. The randomization was performed at the
interview by means of a computerized system, and the
study was designed with the sole purpose of exploring
whether lay people can discriminate between levels of
effectiveness when they are presented in terms of post-
ponement of adverse outcomes.
Similar wording has been used in several other studies,
and has also been tested in focus groups [10,14,17]. An
extended and a limited introductory text was presented in
order to test whether more detailed information on the
actual distribution of benefits and the uncertainty regard-
ing the effect of medication for the individual patient
would change preference patterns.
Subsequently, the respondents were asked whether it was
difficult to understand the effectiveness of the medication
(not difficult, a little difficult, very difficult or impossible
to understand).
The data were analyzed using the STATA statistical pack-
age version 8.0. We tested the hypothesis that increasing
the magnitude of postponement of the heart attack would
increase the respondents' consent to therapy. Consent was
present if the subject answered yes to treatment and not
present if the subject rejected the treatment or stated too
little information was given. We used logistic regression
analysis to explore the association between consent to
therapy and the independent variables. We used the log
with base 2 of number of years postponement because a
doubling in postponement equals + 1 on this scale.
Results
The mean age of the 1,367 respondents was 60 years, 52%
were female, 74% had education beyond elementary
school, and the median family income was in the range
DKK200,000 to DKK400,000 (Table 1). The age and gen-
der distribution was similar to that of the Danish popula-
tion while the respondents had a lower proportion of
individuals with no more than elementary schooling
(26% versus 32% in the general population).
On average 58% of all respondents accepted the hypothet-
ical drug treatment, 30% rejected it and 12% were unde-
cided (Table 2). Amongst those respondents who received
extended information the proportion who accepted was
54% while 62% accepted therapy when presented with
the limited information (p = 0.004). Amongst all respond-
ents the proportions accepting the treatment were 39%,
52%, 56%, 64%, 67% and 73% for postponement of a
heart attack of 1 month, 6 months, 12 months, 2 years, 4
years and 8 years, respectively (Table 2). These results
indicate a trend towards greater acceptance for larger post-
ponements (for statistical test see table 3), but the incre-
mental increase in the proportions accepting diminished
with increasing postponement (Table 2).
Previous heart attack was reported by 5% of the respond-
ents, and 18% reported hypercholesterolemia. These
respondents were more likely to accept the hypothetical
treatment than their counterparts without personal expe-
rience with these diseases (p = 0.008 and p < 0.001).
In total 81% of the respondents indicated that the effec-
tiveness information was not difficult to understand,
while others found it somewhat difficult (14%), very dif-
ficult (4%) or impossible to understand (2%) (Table 2).
There was no difference in level of understanding across
postponement groups. Respondents who had no difficul-
ties in understanding the information were more likely toBMC Medical Informatics and Decision Making 2007, 7:8 http://www.biomedcentral.com/1472-6947/7/8
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accept the hypothetical treatment (p ≤ 0.001) (table 3).
This trend was seen in the group given the limited version
of information as well as in the group given the extended
information. Presentation of extended information did
not impact on perceived understanding of the informa-
tion (chi2 = 0.102; p = 0.992).
The results were confirmed in a logistic regression analysis
of consent to therapy (Table 3). Here, male gender (odds
ratio (OR) 0.77, 95% confidence interval (CI) 0.61–0.97),
level of understanding, elevated cholesterol level (OR
1.85, CI 1.75–2.58) and previous myocardial infarction
(OR 2.53, CI 1.28–5.00) increased the odds for consent-
ing to therapy. The odds also increased with increasing
effectiveness of the therapy (postponement of heart
attack), but decreased when extended information were
presented. The effect of age on consent to therapy was
inconsistent, and there was no significant effect of educa-
tional attainment. Household income was omitted from
the regression analysis due to multi-collinearity.
Discussion
In this randomized study, the participants could discrim-
inate between different levels of effectiveness when they
Table 2: Consent to therapy and self reported understanding of information given. Percentages in parentheses
Postponement of heart attack
1 month 6 months 12 months 2 years 4 years 8 years Total
Consent to therapy
Yes 88 (39) 115 (52) 135 (56) 156 (64) 143 (67) 160 (73) 797 (58)
No 112 (50) 77 (35) 72 (30) 62 (25) 47 (22) 38 (17) 408 (30)
Too little information 26 (12) 28 (13) 36 (15) 26 (11) 24 (11) 22 (10) 162 (12)
Level of understanding
Not difficult 177 (78) 170 (77) 192 (79) 210 (86) 174 (81) 179 (81) 1102 (81)
A little difficult 35 (16) 32 (15) 37 (15) 29 (12) 26 (12) 28 (13) 187 (14)
Very difficult 11 (5) 11 (5) 8 (3) 4 (2) 6 (3) 11 (5) 57 (4)
Impossible to understand 3 (1) 7 (3) 6 (2) 1 (0) 8 (4) 2 (0) 27 (2)
Table 1: Characteristics of respondents randomly allocated to different magnitudes of treatment effectiveness expressed in terms of 
postponement of heart attack. Percentages in parentheses
Postponement of heart attack
1 month 6 months 12 months 2 years 4 years 8 years Total Danish population*
Total 226 220 243 244 214 220 1367 2669018
Age 40–49 53 (23) 60 (27) 69 (28) 80 (33) 58 (27) 52 (24) 372 (27) 776802 (29)
50–59 61 (27) 69 (31) 60 (25) 63 (26) 44 (21) 59 (27) 356 (26) 743971 (28)
60–69 57 (25) 44 (20) 51 (21) 37 (15) 56 (26) 47 (21) 292 (21) 574939 (22)
70–79 37 (16) 28 (13) 42 (17) 46 (19) 32 (15) 37 (17) 222 (16) 351450 (13)
80+ 18 (8) 19 (9) 21 (9) 18 (7) 24 (11) 25 (11) 125 (9) 221856 (8)
Gender Women 108 (48) 121 (55) 130 (53) 124 (51) 109 (51) 125 (57) 717 (52) 1386709 (52)
Educational Attainment# Low 60 (27) 62 (28) 68 (28) 62 (25) 47 (22) 59 (27) 358 (26) (32)
Intermediate 111 (49) 97 (44) 110 (45) 106 (43) 111 (52) 104 (47) 639 (47) (43)
High 55 (24) 61 (28) 65 (27) 76 (31) 56 (26) 57 (26) 370 (27) (25)
Elevated cholesterol level Yes 48 (21) 43 (20) 37 (15) 42 (17) 39 (18) 38 (17) 247 (18) Data not available
No/Don't know 178 (79) 177 (80) 206 (85) 202 (83) 175 (82) 182 (83) 1120 (82)
Myocardial Infarction Yes 14 (6) 10 (5) 11 (5) 9 (4) 10 (5) 14 (6) 68 (5) Data not available
No/Don't know 212 (94) 210 (95) 232 (95) 235 (96) 204 (95) 206 (94) 1299 (95)
Household Income (DKK1,000) 0–200 75 (33) 55 (25) 69 (28) 53 (22) 65 (30) 66 (30) 383 (28) Data not available
200–400 52 (23) 55 (25) 69 (28) 55 (23) 52 (24) 61 (28) 344 (25)
400–600 37 (16) 47 (21) 53 (22) 63 (26) 32 (15) 41 (19) 273 (20)
600- 32 (14) 38 (17) 27 (11) 43 (18) 33 (15) 33 (15) 206 (15)
Don't know/denied response 30 (13) 25 (11) 25 (10) 30 (12) 32 (15) 19 (9) 161 (12)
* [20]
# Data on educational attainment for the Danish population covers age 40–69 years. Data on the population aged 70+ are not availableBMC Medical Informatics and Decision Making 2007, 7:8 http://www.biomedcentral.com/1472-6947/7/8
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were presented in terms of postponement of a heart
attack. The results may indicate that postponement of
adverse health outcomes can be used to convey informa-
tion about treatment effectiveness for lay people.
This interpretation, however, should be seen against the
limitations of the study. First the response rate was rela-
tively low (50%), and data on background variables indi-
cate that the study sample was not entirely representative
of the Danish population. The internal validity, however,
may be good in that the groups were balanced in terms of
background variables. Secondly we can only observe that
the participants could discriminate between different lev-
els of effectiveness, but we do not know how they inter-
preted this effectiveness information. The participants
may assume that the postponement is "tacked" onto a dis-
ease-free average lifespan [18] not realizing that the gain
of the preventive intervention could be in the near future.
Likewise, respondents may perceive the postponement as
"guaranteed" not realizing that one cannot predict the
benefit to the individual patient. The extended informa-
tion addresses these issues, and the reduction in propen-
sity to participate observed amongst those respondents
presented with this added information, suggests that
some individuals may be steered by such miscomprehen-
sions.
The findings in our study accord with another study [14]
demonstrating that lay people seem to discriminate
between treatment effectiveness when it is expressed as
postponement of hip fracture. It is also seen that partici-
pants with hypercholesterolemia or previous heart attack
are more likely to accept the treatment supporting the
findings of previous studies that show that patients in sec-
ondary prevention are more likely to continue therapy [3].
Our results, however, are in contrast to previous studies
which show that lay people have difficulties in discrimi-
nating between levels of effectiveness when they are pre-
sented in terms of NNT [10,11,17]. The explanation of
this discrepancy may be that risk reductions are generally
difficult to comprehend, and respondents may be misled
by the so-called "evaluability heuristics". This implies that
they base their decisions on cues that they are able to
understand (e.g. cost of therapy or side effects) rather than
Table 3: Multivariate logistic regression analysis of the odds for consenting to therapy. (0 = "no" or "uncertain", 1 = "yes", N = 1,367)
Variable Odds ratio 95% Confidence interval p
Intervention effectiveness (Log (base 2) of years postponement of myocardial infarction) 1,266 1.198;1.338 <0.001
Extended information or not (with or without presentation of baseline risk)
No (=0) 1-
Yes (=1) 0.690 0.548;0.869 0.002
Level of understanding
Not difficult 1- -
A little difficult 0.488 0.349; 0.682 <0.001
Very difficult 0.384 0.208; 0.709 0.002
Impossible to understand 0.239 0.100;0.571 0,001
Elevated cholesterol level
No/don't know (=0) 1-
Yes (=1) 1.852 1.751:2.577 <0.001
Myocardial infarction
No/don't know (=0) 1- -
Yes (=1) 2.527 1.276;5.000 0.008
Age
40–49 1- -
50–59 1.554 1.138;2.124 0.006
60–69 1.373 0.985;1.912 0.061
70–79 1.836 1.265;2.664 0.001
80+ 0.965 0.615;1.514 0.876
Educational attainment
Low 1- -
Intermediate 1.053 0.789;1.406 0.725
High 0.959 0.693;1.326 0.801
Gender
Male (=0) 1- -
Female (=1) 0.770 0.610;0,971 0.027BMC Medical Informatics and Decision Making 2007, 7:8 http://www.biomedcentral.com/1472-6947/7/8
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information that is difficult to evaluate (e.g. treatment
effectiveness presented as risk reductions). In contrast,
most people can relate to time and differences in time.
Whether postponement of adverse health outcomes can
be a useful tool for shared decision making remains to be
shown in studies undertaken in a clinical context. The
benefits of interventions are unlikely to be evenly spread
among patients. The distribution of health gains is gener-
ally more complex and cannot be adequately described by
way of postponement or risk reductions. Ideally, we need
a two dimensional measure which can describe the prob-
ability of gain as well as the postponement of adverse
events amongst those who gain. However, survival curves
from clinical trials do not provide us with such detailed
knowledge of the distribution of health benefits. Simula-
tion tests (not shown here) indicate that survival curves
have similar appearance irrespective of whether all
patients gain 6 months or 1 in 10 patients gain 60
months. One might suspect that patients' preferences are
not equal for these two alternatives. Also, it should be
noted that some patients may be discouraged when they
learn that most health interventions prolong life by less
than 12 months [19]. Finally, people may find it odd to
think about the therapeutic benefits in terms of postpone-
ment of heart attack or hip fracture. The widespread use of
the term prevention would indicate that the adverse out-
comes are avoided rather than postponed.
Conclusion
We conclude that postponement of adverse health out-
comes is an alternative measure of effectiveness that
seems to allow laypersons to discriminate between levels
of effectiveness. More research is needed to explore
whether postponement of adverse events in practice is
useful for shared decision making.
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